A case of acute myelofibrosis with complex karyotypic changes: A type of myelodysplastic syndrome

Allen, Elizabeth F.; Lunde, John H.; McNally, R.; Branda, Richard E.

doi:10.1016/0165-4608(96)00037-4

Cited by 7 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This case highlights the importance of identifying and differentiating APMF from other entities like AML-M7 and RAEB-2 so that aggressive treatment can be instituted. This case also confirms that APMF is a type of AML unlike many who believed it to be a type of MDS 3,4,5,6…”

Section: Discussionsupporting

confidence: 76%

“…Though it may be extremely difficult to differentiate APMF from its mimickers in some cases, detailed clinical history and hematological work up can be helpful in such cases. Many consider, as evidenced by many published articles, that APMF is a variant of MDS 3,4,5,6. Since the outcome of these patients is poor therefore it is important to aggressively manage these patients with timely diagnosis as it can reduce morbidity and prolong life.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia

Chatterjee¹,

Gupta

Sharma³

et al. 2013

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

One case of acute panmyelosis with myelofibrosis (APMF) is here reported. A 45 year old male presented with abrupt onset of rapidly progressing low backache, weakness and pancytopenia. On examination there was no organomegaly. Peripheral blood examination revealed normocytic normochromic red blood cells with 10% circulating blasts. Flowcytometric examination of peripheral blood revealed blasts which were positive for CD34, HLA− DR and myeloid associated antigens (i.e. CD13 and CD33). Blasts were negative for anti MPO. Bone marrow aspirate resulted in a dry tap. Bone marrow biopsy revealed panmyeloid proliferation with scattered blasts which were CD34 positive on imunohistochemistry and negative for anti MPO. Reticulin stain showed grade III myelofibrosis (WHO). Differential diagnosis considered included AML-M7, MDS-RAEB II and AML with myelodysplasia. He was started on chemotherapy [idarubicin and cytarabine; 3+7 induction regimen followed by three cycles of HIDAC (High dose cytosine arabinoside)] after which patient was in complete morphological remission with markedly reduced bone marrow fibrosis. He is now being worked up for allogeneic stem cell transplantation. Patient is asymptomatic at eight months of diagnosis. In conclusion these patients should be managed aggressively with AML therapy and this case report reaffirms the fact that APMF is subtype of AML.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia

Chatterjee¹,

Gupta

Sharma³

et al. 2013

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

“…Cytogenetic features of MDS-F include monosomy 7 [9,16,28]. Complex or other unique cytogenetic features have been reported [7,9,16,[28][29][30][31][32]. Fu, et al [24] studied 266 t-MDS patients and reported that monosomy 5 and monosomy 17 were more commonly detected in t-MDS patients with MF-2/3 (P = 0.031 and P = 0.043, respectively).…”

Section: Genotype Of Primary Mds With Fibrosismentioning

confidence: 99%

“…Cytogenetic features of MDS-F include monosomy 7 [ 9 , 16 , 28 ]. Complex or other unique cytogenetic features have been reported [ 7 , 9 , 16 , 28 - 32 ]. Fu, et al .…”

Section: Introductionmentioning

confidence: 99%

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update

et al. 2022

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) is a diverse hematological malignancy with a wide spectrum of presentations and implications. Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international prognostic scoring system (IPSS-R). Bone marrow fibrosis (BMF) has been identified as an independent risk factor for poor survival in patients with MDS, irrespective of the IPSS-R risk category. However, BMF is not widely included in scoring systems and is not always considered by clinicians when making treatment decisions for patients. In this review, we discuss the available literature about the presentation and prognosis of patients with MDS and concurrent BMF. The prognostic impact of BMF should be factored in when deciding on transplant candidacy, especially for intermediate-risk patients.

show abstract

“…47-49 Elizabeth E et al indicated that if MDS is accompanied with fibrosis and chromosomal abnormalities, the prognosis will be poorer than the case MDS is associated with chromosomal abnormalities without fibrosis (Table 1). 50 Therefore, BM biopsy together with cytogenetic study is suggested in MDS patients presenting with a decrease in hematopoietic cell lineages and splenomegaly.…”

Section: Myelofibrosis and Complex Karyotypementioning

confidence: 99%

Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility

Shahjahani¹,

Hadad²,

Azizidoost³

et al. 2019

Oncol Rev

View full text Add to dashboard Cite

Complex karyotype (CK) is a poor prognosis factor in hematological malignancies. Studies have shown that the presence of CK in myelodysplastic syndrome (MDS) can be associated with MDS progression to acute myeloid leukemia. The goal of this review was to examine the relationship between different types of CK with MDS, as well as its possible role in the deterioration and progression of MDS to leukemia. The content used in this paper has been obtained by a PubMed and Google Scholar search of English language papers (1975-2018) using the terms complex karyotype and myelodysplastic syndromes. A single independent abnormality can be associated with a good prognosis. However, the coexistence of a series of abnormalities can lead to CK, which is associated with the deterioration of MDS and its progression to leukemia. Therefore, CK may be referred to as a prognostic factor in MDS. The detection of independent cytogenetic disorders that altogether can result in CK could be used as a prognostic model for laboratory and clinical use.

show abstract

A case of acute myelofibrosis with complex karyotypic changes: A type of myelodysplastic syndrome

Cited by 7 publications

References 22 publications

Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia

Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update

Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility

Contact Info

Product

Resources

About